Tarsus Pharmaceuticals reported second-quarter 2026 net product sales of $173.9 million, a 69% year-over-year increase, and raised its full-year 2026 XDEMVY net product sales guidance to $685-705 million. The company announced the pending acquisition of Alkeus Pharmaceuticals to expand its retina pipeline with a Phase 3 program for Stargardt disease, supported by a priced $125 million private placement financing. Tarsus also completed the acquisition of iRenix Medical and appointed Neera Clase as Interim Chief Commercial Officer. Second-quarter net loss was $18.6 million compared to $20.3 million in the prior year period. The company operates in the pharmaceutical industry, developing treatments for eye care conditions such as Demodex blepharitis.
